SPRY
Research Snapshot
Static fundamentals, valuation context, and investor signals for ARS Pharmaceuticals, Inc. (SPRY).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-81.3%
ROIC, -203.1% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.8x
Debt/equity, 7.3x current ratio
Superinvestors
1
Top: Daniel Loeb (0.4%)
Strengths to research
- Debt/equity looks manageable at 0.8x.
Watchouts
- Free cash flow margin is negative at -203.1%.
- Valuation multiples are limited or unavailable.
Annual data: 6 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for SPRY.
Grade F
0
/ 100
Financial Charts
No financial data available for SPRY (annual).
1 superinvestors own SPRY
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Daniel Loeb Third Point | 1,000,000 | $8M | 0.39% | ▲ +79.8% |